Summary of Key Information:

Reporting Period: Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Unaudited Financial Results (Standalone and Consolidated)

Date of Board Meeting / Approval: July 21, 2026 (commenced at 12:25 p.m., concluded at 1:33 p.m.)

Audit Opinion: Clean opinion - no material misstatements identified in limited review

Auditor's Comment: No qualifications or modifications; prepared in accordance with Ind AS 34

Key Financial Highlights [₹ in crore]

Standalone Results:

Revenue from Operations: ₹455.52 (vs. ₹441.93 in Q1 FY26, +3.1% YoY)

Total Income: ₹617.72 (vs. ₹559.49 in Q1 FY26)

Net Profit: ₹311.38 (vs. ₹276.89 in Q1 FY26, +12.5% YoY)

EPS: Basic ₹10.78, Diluted ₹10.74 (not annualized)

Other Equity: Not specified for quarter

Consolidated Results:

Revenue from Operations: Not separately disclosed in consolidated table

Total Income: ₹625.35

Net Profit: ₹309.49

EPS: Basic ₹10.72, Diluted ₹10.67 (not annualized)

Expense Breakdown (Standalone):

Employee Benefit Expense: ₹111.80 (vs. ₹89.45 in Q1 FY26)

Fees and Commission Expense: ₹13.70 (vs. ₹13.47 in Q1 FY26)

Depreciation and Amortization: ₹12.43 (vs. ₹9.99 in Q1 FY26)

Other Expense: ₹71.16 (vs. ₹73.22 in Q1 FY26)

Total Expenses: ₹210.19 (vs. ₹187.43 in Q1 FY26)

Tax Expenses (Standalone):

Current Tax: ₹74.05

Deferred Tax: ₹22.10

Total Tax Expenses: ₹96.15

Subsidiary Performance:

Four wholly-owned subsidiaries included in consolidation with total revenues of ₹9.4 crore and net loss of ₹(1.9) crore for the quarter

Corporate Actions:

Dividend: Final dividend of ₹25.50 per equity share (face value of ₹5 each) approved for FY26, subject to shareholder approval

ESOP Allotment: 397,297 equity shares allotted during quarter under Employee Stock Option Schemes

Pending Allotment: Application money received for 2,500 equity shares

Other Significant Information:

Segment Reporting: No separate reportable segments as primary business is asset management services

Accounting Policy: No changes in accounting policy affecting comparability

Forward-looking Guidance: No specific guidance or outlook provided